Login

Life Science

Avaxia

Avaxia is a clinical-stage biotechnology company that is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. Avaxia’s proprietary oral antibody platform makes direct delivery of antibodies to the GI tract possible by overcoming some of the traditional limitations of antibody therapeutics....

CardioCreate

CardioCreate is pioneering a bold, new approach to heart disease.  Instead of treating the symptoms of heart attack and heart failure, our genetically-engineered stem cells replace damaged heart tissue with healthy, functional heart tissue.  Heart disease is the greatest single component of healthcare costs today, and this regenerative approach could dramatically reduce those expenditures.  Our mission is to advance this promising technology through preclinical development and clinical trials so that it can improve the lives of...

Cognition Therapeutics

Cognition Therapeutics is a drug discovery company using proprietary and biologically-relevant screening and chemistry platforms to closely model the pathology of neurodegenerative diseases. The company’s lead program is focused on the discovery of small molecule therapeutics that block the action of the toxic soluble oligomer proteins that cause the cognitive decline associated with Alzheimer's disease (AD).  This program has identified first-in-class drugs that selectively block soluble Abeta oligomer-induced toxicity on synapse function.  These drugs are...

Infobionic

InfoBionic is an emerging mHealth company with a cloud based solution, MoMe(TM), for comprehensive remote physiological monitoring with a focus on Arrhythmia Detection. Our vision is to be part of the transformation of healthcare delivery by providing anywhere anytime access to cardiac monitoring with higher quality and lower cost with a new business model. MoMe(TM) has a clear regulatory path 510(k) and reimbursement in place.